<!DOCTYPE html>
<html class="client-js"><head>
  <meta charset=UTF-8"UTF-8">
  <title>Thiazolidinedione</title>
  <meta name="viewport" content="width=device-width, initial-scale=1.0">
  <script>
    function importScript() { return 1 } // this is to avoid the error from site.js
  </script>
  <link rel="canonical" href="https://en.wikipedia.org/wiki/Thiazolidinedione">
  <link href="../-/s/css_modules/ext.cite.ux-enhancements.css" tppabs="https://ptable.com/wiki/compounds/-/s/css_modules/ext.cite.ux-enhancements.css" rel="stylesheet" type="text/css" class="">
<link href="../-/s/css_modules/ext.cite.styles.css" tppabs="https://ptable.com/wiki/compounds/-/s/css_modules/ext.cite.styles.css" rel="stylesheet" type="text/css" class="">
<link href="../-/s/css_modules/fi000001.css" tppabs="https://ptable.com/wiki/compounds/-/s/css_modules/skins.minerva.base.reset|skins.minerva.content.styles|ext.cite.style|site.styles|mobile.app.pagestyles.android|mediawiki.page.gallery.styles|mediawiki.skinning.content.parsoid.css" rel="stylesheet" type="text/css" class="">
  <link href="../-/s/css_modules/style.css" tppabs="https://ptable.com/wiki/compounds/-/s/css_modules/style.css" rel="stylesheet" type="text/css" class=""><link href="../-/s/css_modules/content.parsoid.css" tppabs="https://ptable.com/wiki/compounds/-/s/css_modules/content.parsoid.css" rel="stylesheet" type="text/css" class=""><link href="../-/s/css_modules/inserted_style.css" tppabs="https://ptable.com/wiki/compounds/-/s/css_modules/inserted_style.css" rel="stylesheet" type="text/css" class="">
  <script src="../-/j/js_modules/script.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/script.js" class=""></script><script src="../-/j/js_modules/masonry.min.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/masonry.min.js" class=""></script><script src="../-/j/js_modules/article_list_home.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/article_list_home.js" class=""></script><script src="../-/j/js_modules/images_loaded.min.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/images_loaded.min.js" class=""></script><script src="../-/j/js_modules/node_module/details-element-polyfill/dist/details-element-polyfill.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/node_module/details-element-polyfill/dist/details-element-polyfill.js" class=""></script>
<link type="root" href=""></head>

<body class="mediawiki mw-hide-empty-elt ns-0 ns-subject stable skin-minerva action-view animations">
  <div id="mw-mf-viewport" class="feature-header-v2">
    <div id="mw-mf-page-center">
      <div id="content" class="mw-body">
        <a id="top"></a>
        <div id="bodyContent" class="content mw-parser-output">
          
          <div id="mw-content-text" style="direction: ltr;"><h1 class="section-heading" tabindex="0" aria-haspopup="true" data-section-id="0">
  <span class="mw-headline" id="title_0">Thiazolidinedione</span>
</h1>
<div id="mf-section-0" class="mf-section-0" aria-pressed="true" aria-expanded="true">
  <p>The <b>thiazolidinediones</b> <span class="rt-commentedText nowrap"><span class="IPA nopopups noexcerpt">/<span style="border-bottom:1px dotted"><span>θ</span><span>aɪ</span><span>.</span><span>ə</span><span>ˌ</span><span>z</span><span>oʊ</span><span>l</span><span>ɪ</span><span>d</span><span>iː</span><span>n</span><span>ˈ</span><span>d</span><span>aɪ</span><span>.</span><span>oʊ</span><span>n</span></span>/</span></span>,  abbreviated as<b> TZD</b>, also known as <b>glitazones</b> after the prototypical drug ciglitazone,<span class="mw-ref" id="cite_ref-Hulin_1-0"><a href="#cite_note-Hulin-1" style="counter-reset: mw-Ref 1;"><span class="mw-reflink-text">[1]</span></a></span> are a class of heterocyclic compounds consisting of a five-membered C<sub>3</sub>NS ring.  The term usually refers to a family of drugs used in the treatment of diabetes mellitus type 2 that were introduced in the late 1990s.</p>

<p></p>
<div class="thumb tright"><div class="thumbinner" style="width:222px"><img src="../I/m/Thiazolidinedione_functional_group.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/Thiazolidinedione_functional_group.svg.png" data-file-width="512" data-file-height="446" data-file-type="drawing" height="192" width="220"><div class="thumbcaption" style="text-align: left">Functional group</div></div></div>


</div><details data-level="2" open="">
    <summary class="section-heading"><h2 id="Mechanism_of_action">Mechanism of action</h2></summary>
    
<p>Thiazolidinediones or TZDs act by activating PPARs (peroxisome proliferator-activated receptors), a group of nuclear receptors, specific for <i>PPARγ</i> (PPAR-gamma, PPARG). They are thus the PPARG agonists subset of PPAR agonists. The endogenous ligands for these receptors are free fatty acids (FFAs) and eicosanoids. When activated, the receptor binds to DNA in complex with the retinoid X receptor (RXR), another nuclear receptor, increasing transcription of a number of specific genes and decreasing transcription of others. The main effect of expression and repression of specific genes is an increase in the storage of fatty acids in adipocytes, thereby decreasing the amount of fatty acids present in circulation. As a result, cells become more dependent on the oxidation of carbohydrates, more specifically <a href="Glucose.htm" tppabs="https://ptable.com/wiki/compounds/A/Glucose" title="Glucose">glucose</a>, in order to yield energy for other cellular processes.</p>


    <details data-level="3" open="">
    <summary class="section-heading"><h3 id="PPARγ_transactivation">PPARγ transactivation</h3></summary>
    
<div class="thumb tright"><div class="thumbinner" style="width:222px"><img src="../I/m/Transactivation_upload.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/Transactivation_upload.svg.png" data-file-width="1647" data-file-height="784" data-file-type="drawing" height="105" width="220"><div class="thumbcaption" style="text-align: left">Thiazolidinedione ligand dependent transactivation is responsible for the majority of anti-diabetic effects.</div></div></div>
<p>The activated PPAR/RXR heterodimer binds to peroxisome proliferator hormone response elements upstream of target genes in complex with a number of coactivators such as nuclear receptor coactivator 1 and CREB binding protein, this causes upregulation of genes (for a full list see PPARγ):</p>
<ul><li>Insulin resistance is decreased</li>
<li>Adipocyte differentiation is modified<span class="mw-ref" id="cite_ref-pmid20158086_2-0"><a href="#cite_note-pmid20158086-2" style="counter-reset: mw-Ref 2;"><span class="mw-reflink-text">[2]</span></a></span></li>
<li>VEGF-induced angiogenesis is inhibited<span class="mw-ref" id="cite_ref-3"><a href="#cite_note-3" style="counter-reset: mw-Ref 3;"><span class="mw-reflink-text">[3]</span></a></span></li>
<li>Leptin levels decrease (leading to an increased appetite)</li>
<li>Levels of certain interleukins (e.g. IL-6) fall</li>
<li>Antiproliferative action</li>
<li>Adiponectin levels rise</li></ul>

<p>TZDs also increase the synthesis of certain proteins involved in fat and glucose metabolism, which reduces levels of certain types of lipids, and circulating free fatty acids. TZDs generally decrease triglycerides and increase high-density lipoprotein cholesterol (HDL-C) and low-density lipoprotein cholesterol (LDL-C).  Although the increase in LDL-C may be more focused on the larger LDL particles, which may be less atherogenic, the clinical significance of this is currently unknown. Nonetheless, rosiglitazone, a certain glitazone, was suspended from allowed use by medical authorities in Europe, as it has been linked to an increased risk of heart attack and stroke.<span class="mw-ref" id="cite_ref-4"><a href="#cite_note-4" style="counter-reset: mw-Ref 4;"><span class="mw-reflink-text">[4]</span></a></span></p>


</details>
<details data-level="3" open="">
    <summary class="section-heading"><h3 id="PPARγ_transrepression">PPARγ transrepression</h3></summary>
    
<div class="thumb tright"><div class="thumbinner" style="width:222px"><img src="../I/m/PPAR_transrepression.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/PPAR_transrepression.svg.png" data-file-width="1655" data-file-height="967" data-file-type="drawing" height="129" width="220"><div class="thumbcaption" style="text-align: left">Thiazolidinedione ligand dependent transrepression mediates the majority of anti-inflammatory effects.</div></div></div>
<p>Binding of PPARγ to coactivators appears to reduce the levels of coactivators available for binding to pro-inflammatory transcription factors such as NF-κB; this causes a decrease in transcription of a number of pro inflammatory genes, including various interleukins and tumour necrosis factors.</p>


</details>

</details><details data-level="2" open="">
    <summary class="section-heading"><h2 id="Members_of_the_class">Members of the class</h2></summary>
    
<div class="thumb tright"><div class="thumbinner" style="width:277px"><img src="../I/m/Thiazolidinedione_and_rhodanine.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/Thiazolidinedione_and_rhodanine.svg.png" data-file-width="512" data-file-height="212" data-file-type="drawing" height="114" width="275"><div class="thumbcaption" style="text-align: left">The chemical structure of thiazolidinedione and rhodanine</div></div></div>
<p>Chemically, the members of this class are derivatives of the parent compound thiazolidinedione, and include:</p>
<ul><li><a href="Pioglitazone.htm" tppabs="https://ptable.com/wiki/compounds/A/Pioglitazone" title="Pioglitazone">Pioglitazone</a> (Actos), France and Germany have suspended its sale after a study suggested the drug could raise the risk of bladder cancer.<span class="mw-ref" id="cite_ref-5"><a href="#cite_note-5" style="counter-reset: mw-Ref 5;"><span class="mw-reflink-text">[5]</span></a></span></li>
<li><a href="javascript:if(confirm('https://ptable.com/wiki/compounds/A/Rosiglitazone  \n\nThis file was not retrieved by Teleport VLX, because it was unavailable, or its retrieval was aborted, or the project was stopped too soon.  \n\nDo you want to open it from the server?'))window.location='https://ptable.com/wiki/compounds/A/Rosiglitazone'" tppabs="https://ptable.com/wiki/compounds/A/Rosiglitazone" title="Rosiglitazone">Rosiglitazone</a> (Avandia), which was put under selling restrictions in the US and withdrawn from the market in Europe due to some studies suggesting an increased risk of cardiovascular events. Upon re-evaluation of new data in 2013, the FDA lifted the restrictions.</li>
<li>Lobeglitazone (Duvie), approved for use in Korea</li></ul>

<p>Experimental, failed and non-marketed agents include:</p>
<ul><li>Ciglitazone</li>
<li>Darglitazone</li>
<li>Englitazone</li>
<li>Netoglitazone</li>
<li>Rivoglitazone</li>
<li><a href="Troglitazone.htm" tppabs="https://ptable.com/wiki/compounds/A/Troglitazone" title="Troglitazone">Troglitazone</a> (Rezulin), withdrawn due to increased incidence of drug-induced hepatitis.</li>
<li>Balaglitazone (DRF-2593) - developed by Dr Reddy's Laboratories, discontinued during 2010-11 phase III trials as no better than available molecules.</li></ul>

<p>Replacing one oxygen atom in a thiazolidinedione with an atom of sulfur gives a <a href="Rhodanine.htm" tppabs="https://ptable.com/wiki/compounds/A/Rhodanine" title="Rhodanine">rhodanine</a>.</p>


    
</details><details data-level="2" open="">
    <summary class="section-heading"><h2 id="Uses">Uses</h2></summary>
    
<p>The only approved use of the thiazolidinediones is in diabetes mellitus type 2. According to a 2014 Cochrane systematic review of four randomized controlled trials, PPARγ-agonists may be effective in preventing further strokes in those who have already had a stroke or a transient ischemic attack (TIA) and may stabilize atherosclerotic plaques in the carotid arteries.<span class="mw-ref" id="cite_ref-CochraneStroke_6-0"><a href="#cite_note-CochraneStroke-6" style="counter-reset: mw-Ref 6;"><span class="mw-reflink-text">[6]</span></a></span></p>


    
</details><details data-level="2" open="">
    <summary class="section-heading"><h2 id="Research">Research</h2></summary>
    
<p>Experimental investigations on TZDs have been carried out since 2005 in polycystic ovary syndrome (PCOS), non-alcoholic steatohepatitis (NASH),<span class="mw-ref" id="cite_ref-NASH_7-0"><a href="#cite_note-NASH-7" style="counter-reset: mw-Ref 7;"><span class="mw-reflink-text">[7]</span></a></span><span class="mw-ref" id="cite_ref-8"><a href="#cite_note-8" style="counter-reset: mw-Ref 8;"><span class="mw-reflink-text">[8]</span></a></span> psoriasis,<span class="mw-ref" id="cite_ref-9"><a href="#cite_note-9" style="counter-reset: mw-Ref 9;"><span class="mw-reflink-text">[9]</span></a></span> autism,<span class="mw-ref" id="cite_ref-10"><a href="#cite_note-10" style="counter-reset: mw-Ref 10;"><span class="mw-reflink-text">[10]</span></a></span> ovarian hyperstimulation syndrome (by VEGF inhibition in granulosa cells),<span class="mw-ref" id="cite_ref-11"><a href="#cite_note-11" style="counter-reset: mw-Ref 11;"><span class="mw-reflink-text">[11]</span></a></span> lichen planopilaris, and other conditions.<span class="mw-ref" id="cite_ref-trials_12-0"><a href="#cite_note-trials-12" style="counter-reset: mw-Ref 12;"><span class="mw-reflink-text">[12]</span></a></span></p>

<p>Several forms of lipodystrophy cause insulin resistance, which has responded favorably to thiazolidinediones. There are some indications that thiazolidinediones provide some degree of protection against the initial stages of breast carcinoma development.</p>

<p>Evidence was emerging in 2008 that <a href="Vitamin_E.htm" tppabs="https://ptable.com/wiki/compounds/A/Vitamin_E" title="Vitamin E">vitamin E</a> with thiazolidinediones is effective in the treatment of non-alcoholic steatohepatitis due to their combined antioxidant and insulin sensitizing effects, producing histological improvements in steatosis severity.<span class="mw-ref" id="cite_ref-13"><a href="#cite_note-13" style="counter-reset: mw-Ref 13;"><span class="mw-reflink-text">[13]</span></a></span></p>


    
</details><details data-level="2" open="">
    <summary class="section-heading"><h2 id="Side_effects_and_contraindications">Side effects and contraindications</h2></summary>
    
<p>The withdrawal of <a href="Troglitazone.htm" tppabs="https://ptable.com/wiki/compounds/A/Troglitazone" title="Troglitazone">troglitazone</a> has led to concerns of the other thiazolidinediones also increasing the incidence of hepatitis and potential liver failure, an approximately 1 in 20,000 individual occurrence with troglitazone. Because of this, the FDA recommends two to three month checks of liver enzymes for the first year of thiazolidinedione therapy to check for this rare but potentially catastrophic complication. To date, 2008, the newer thiazolidinediones, <a href="javascript:if(confirm('https://ptable.com/wiki/compounds/A/Rosiglitazone  \n\nThis file was not retrieved by Teleport VLX, because it was unavailable, or its retrieval was aborted, or the project was stopped too soon.  \n\nDo you want to open it from the server?'))window.location='https://ptable.com/wiki/compounds/A/Rosiglitazone'" tppabs="https://ptable.com/wiki/compounds/A/Rosiglitazone" title="Rosiglitazone">rosiglitazone</a> and <a href="Pioglitazone.htm" tppabs="https://ptable.com/wiki/compounds/A/Pioglitazone" title="Pioglitazone">pioglitazone</a> have been free of this problem.</p>

<p>The main side effect of all thiazolidinediones is water retention, leading to edema, generally a problem in less than 5% of individuals, but a big problem for some and potentially, with significant water retention, leading to a decompensation of potentially previously unrecognized heart failure. Therefore, thiazolidinediones should be prescribed with both caution and patient warnings about the potential for water retention/weight gain, especially in patients with decreased ventricular function (NYHA grade III or IV heart failure).</p>

<p>Though older studies suggested there may be an increased risk of coronary heart disease and heart attacks with rosiglitazone,<span class="mw-ref" id="cite_ref-14"><a href="#cite_note-14" style="counter-reset: mw-Ref 14;"><span class="mw-reflink-text">[14]</span></a></span> <a href="Pioglitazone.htm" tppabs="https://ptable.com/wiki/compounds/A/Pioglitazone" title="Pioglitazone">pioglitazone</a> treatment, in contrast, has shown significant protection from both micro- and macro-vascular cardiovascular events and plaque progression.<span class="mw-ref" id="cite_ref-15"><a href="#cite_note-15" style="counter-reset: mw-Ref 15;"><span class="mw-reflink-text">[15]</span></a></span><span class="mw-ref" id="cite_ref-Pioglitazone_and_cardiovascular_risk_16-0"><a href="#cite_note-Pioglitazone_and_cardiovascular_risk-16" style="counter-reset: mw-Ref 16;"><span class="mw-reflink-text">[16]</span></a></span><span class="mw-ref" id="cite_ref-Nissen_17-0"><a href="#cite_note-Nissen-17" style="counter-reset: mw-Ref 17;"><span class="mw-reflink-text">[17]</span></a></span> These studies led to a period of Food and Drug Administration advisories (2007 - 2013) that, aided by extensive media coverage, led to a substantial decrease in rosiglitazone use. In November 2013, the FDA announced it would remove the usage restrictions for rosiglitazone in patients with coronary artery disease.<span class="mw-ref" id="cite_ref-18"><a href="#cite_note-18" style="counter-reset: mw-Ref 18;"><span class="mw-reflink-text">[18]</span></a></span> The new recommendations were largely based on the reasoning that prior meta-analyses leading to the original restrictions were not designed to assess cardiac outcomes and, thus, not uniformly collected or adjudicated.  In contrast, one of the largest trials (RECORD trial) that was specifically designed to assess cardiac outcomes found no increased risk of  myocardial infarction with rosiglitazone use, even after independent re-evaluation for FDA review.<span class="mw-ref" id="cite_ref-19"><a href="#cite_note-19" style="counter-reset: mw-Ref 19;"><span class="mw-reflink-text">[19]</span></a></span></p>

<p>A 2013 meta-analysis concluded that use of <a href="Pioglitazone.htm" tppabs="https://ptable.com/wiki/compounds/A/Pioglitazone" title="Pioglitazone">pioglitazone</a> is associated with a slightly higher risk of bladder cancer compared to the general population. The authors of the same analysis recommended that other blood sugar lowering agents be considered in people with other risk factors for bladder cancer such as cigarette smoking, family history, or exposure to certain forms of chemotherapy.<span class="mw-ref" id="cite_ref-Ferwana2013_20-0"><a href="#cite_note-Ferwana2013-20" style="counter-reset: mw-Ref 20;"><span class="mw-reflink-text">[20]</span></a></span></p>

<p>Thiazolidinediones reduce bone mineral density and increase the risk of fractures in women, possibly as a result of biasing the differentiation of bone marrow stromal cells away from osteoblast differentiation and toward adipocyte formation.<span class="mw-ref" id="cite_ref-Man&amp;Dic2015_21-0"><a href="#cite_note-Man&amp;Dic2015-21" style="counter-reset: mw-Ref 21;"><span class="mw-reflink-text">[21]</span></a></span></p>

<p>Thiazolidinediones increase expression of angiotensin-converting enzyme 2 (ACE2). It is hypothesized that this increases the chance of serious infection with the SARS-CoV-2 virus, which causes COVID-19.<span class="mw-ref" id="cite_ref-FengKaraRoth2020_22-0"><a href="#cite_note-FengKaraRoth2020-22" style="counter-reset: mw-Ref 22;"><span class="mw-reflink-text">[22]</span></a></span></p>


    
</details><details data-level="2" open="">
    <summary class="section-heading"><h2 id="References">References</h2></summary>
    
<div class="reflist columns references-column-width" style="-moz-column-width: 30em; -webkit-column-width: 30em; column-width: 30em; list-style-type: decimal;">
<ol class="mw-references references"><li id="cite_note-Hulin-1"> <span id="mw-reference-text-cite_note-Hulin-1" class="mw-reference-text"><cite id="CITEREFHulinMcCarthyGibbs1996" class="citation journal cs1">Hulin B, McCarthy PA, Gibbs EM (1996). <a href="javascript:if(confirm('https://books.google.com/books?id=IYn4Va7wtAoC&pg=PA86&dq=ciglitazone  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://books.google.com/books?id=IYn4Va7wtAoC&pg=PA86&dq=ciglitazone'" tppabs="https://books.google.com/books?id=IYn4Va7wtAoC&pg=PA86&dq=ciglitazone" class="external text external">"The glitazone family of antidiabetic agents"</a>. <i>Current Pharmaceutical Design</i>. <b>2</b>: 85–102.</cite></span></li><li id="cite_note-pmid20158086-2"> <span id="mw-reference-text-cite_note-pmid20158086-2" class="mw-reference-text"><cite id="CITEREFWakiYamauchiKadowaki2010" class="citation journal cs1">Waki, H; Yamauchi, T; Kadowaki, T (2010). "Regulation of differentiation and hypertrophy of adipocytes and adipokine network by PPARgamma". <i>Nihon Rinsho</i>. <b>68</b> (2): 210–6. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/20158086  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/20158086'" tppabs="https://pubmed.ncbi.nlm.nih.gov/20158086" class="external text external">20158086</a>.</cite></span></li><li id="cite_note-3"> <span id="mw-reference-text-cite_note-3" class="mw-reference-text"><cite id="CITEREFPanigrahySingerShenButterfield2002" class="citation journal cs1">Panigrahy, Dipak; Singer, Samuel; Shen, Lucy Q.; Butterfield, Catherine E.; Freedman, Deborah A.; Chen, Emy J.; Moses, Marsha A.; Kilroy, Susan; Duensing, Stefan; Fletcher, Christopher; Fletcher, Jonathan A.; Hlatky, Lynn; Hahnfeldt, Philip; Folkman, Judah; Kaipainen, Arja (2002). <a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC151148  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC151148'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC151148" class="external text external">"PPARγ ligands inhibit primary tumor growth and metastasis by inhibiting angiogenesis"</a>. <i>Journal of Clinical Investigation</i>. <b>110</b> (7): 923–32. doi:<a href="javascript:if(confirm('https://doi.org/10.1172%2FJCI15634  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1172%2FJCI15634'" tppabs="https://doi.org/10.1172%2FJCI15634" class="external text external">10.1172/JCI15634</a>. PMC<span>&nbsp;</span><span class="cs1-lock-free"><a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC151148  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC151148'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC151148" class="external text external">151148</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/12370270  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/12370270'" tppabs="https://pubmed.ncbi.nlm.nih.gov/12370270" class="external text external">12370270</a>.</cite></span></li><li id="cite_note-4"> <span id="mw-reference-text-cite_note-4" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('http://www.nhs.uk/news/2010/09September/Pages/rosiglitazone-avandia-drug-suspended-heart-risk.aspx  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.nhs.uk/news/2010/09September/Pages/rosiglitazone-avandia-drug-suspended-heart-risk.aspx'" tppabs="http://www.nhs.uk/news/2010/09September/Pages/rosiglitazone-avandia-drug-suspended-heart-risk.aspx" class="external text external">"Avandia diabetes drug suspended"</a>. <i>nhs.uk</i>. 24 September 2010.</cite></span></li><li id="cite_note-5"> <span id="mw-reference-text-cite_note-5" class="mw-reference-text"><a href="javascript:if(confirm('http://www.huliq.com/3257/diabetes-drug-actos-sales-suspended-france-and-germany%5B%5D  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.huliq.com/3257/diabetes-drug-actos-sales-suspended-france-and-germany%5B%5D'" tppabs="http://www.huliq.com/3257/diabetes-drug-actos-sales-suspended-france-and-germany%5B%5D" class="external free external">http://www.huliq.com/3257/diabetes-drug-actos-sales-suspended-france-and-germany%5B%5D</a></span></li><li id="cite_note-CochraneStroke-6"> <span id="mw-reference-text-cite_note-CochraneStroke-6" class="mw-reference-text"><cite id="CITEREFLiuWang2015" class="citation journal cs1">Liu, Jia; Wang, Lu-Ning (October 2015). "Peroxisome proliferator-activated receptor gamma agonists for preventing recurrent stroke and other vascular events in patients with stroke or transient ischaemic attack". <i>Cochrane Database of Systematic Reviews</i> (10): CD010693. doi:<a href="javascript:if(confirm('https://doi.org/10.1002%2F14651858.CD010693.pub3  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1002%2F14651858.CD010693.pub3'" tppabs="https://doi.org/10.1002%2F14651858.CD010693.pub3" class="external text external">10.1002/14651858.CD010693.pub3</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/26511368  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/26511368'" tppabs="https://pubmed.ncbi.nlm.nih.gov/26511368" class="external text external">26511368</a>.</cite></span></li><li id="cite_note-NASH-7"> <span id="mw-reference-text-cite_note-NASH-7" class="mw-reference-text"><cite id="CITEREFBelfortHarrisonBrownDarland2006" class="citation journal cs1">Belfort, Renata; Harrison, Stephen A.; Brown, Kenneth; Darland, Celia; Finch, Joan; Hardies, Jean; Balas, Bogdan; Gastaldelli, Amalia; Tio, Fermin; Pulcini, Joseph; Berria, Rachele; Ma, Jennie Z.; Dwivedi, Sunil; Havranek, Russell; Fincke, Chris; Defronzo, Ralph; Bannayan, George A.; Schenker, Steven; Cusi, Kenneth (2006). "A Placebo-Controlled Trial of Pioglitazone in Subjects with Nonalcoholic Steatohepatitis". <i>New England Journal of Medicine</i>. <b>355</b> (22): 2297–307. doi:<a href="javascript:if(confirm('https://doi.org/10.1056%2FNEJMoa060326  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1056%2FNEJMoa060326'" tppabs="https://doi.org/10.1056%2FNEJMoa060326" class="external text external">10.1056/NEJMoa060326</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/17135584  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/17135584'" tppabs="https://pubmed.ncbi.nlm.nih.gov/17135584" class="external text external">17135584</a>.</cite></span></li><li id="cite_note-8"> <span id="mw-reference-text-cite_note-8" class="mw-reference-text"><span>Clinical trial number </span><i><a href="javascript:if(confirm('https://www.clinicaltrials.gov/show/NCT00227110  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.clinicaltrials.gov/show/NCT00227110'" tppabs="https://www.clinicaltrials.gov/show/NCT00227110" class="external text external">NCT00227110</a></i><span> for "Role of Pioglitazone in the Treatment of Non-alcoholic Steatohepatitis (NASH)" at </span>ClinicalTrials.gov</span></li><li id="cite_note-9"> <span id="mw-reference-text-cite_note-9" class="mw-reference-text"><cite id="CITEREFKrentzFriedmann2006" class="citation journal cs1">Krentz, A. J.; Friedmann, P. S. (2006). "Type 2 diabetes, psoriasis and thiazolidinediones". <i>International Journal of Clinical Practice</i>. <b>60</b> (3): 362–3. doi:<a href="javascript:if(confirm('https://doi.org/10.1111%2Fj.1368-5031.2005.00765.x  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1111%2Fj.1368-5031.2005.00765.x'" tppabs="https://doi.org/10.1111%2Fj.1368-5031.2005.00765.x" class="external text external">10.1111/j.1368-5031.2005.00765.x</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/16494655  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/16494655'" tppabs="https://pubmed.ncbi.nlm.nih.gov/16494655" class="external text external">16494655</a>.</cite></span></li><li id="cite_note-10"> <span id="mw-reference-text-cite_note-10" class="mw-reference-text"><cite id="CITEREFBorisKaiserGoldblattElice2007" class="citation journal cs1">Boris, Marvin; Kaiser, Claudia C; Goldblatt, Allan; Elice, Michael W; Edelson, Stephen M; Adams, James B; Feinstein, Douglas L (2007). <a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1781426  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1781426'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1781426" class="external text external">"Effect of pioglitazone treatment on behavioral symptoms in autistic children"</a>. <i>Journal of Neuroinflammation</i>. <b>4</b>: 3. doi:<a href="javascript:if(confirm('https://doi.org/10.1186%2F1742-2094-4-3  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1186%2F1742-2094-4-3'" tppabs="https://doi.org/10.1186%2F1742-2094-4-3" class="external text external">10.1186/1742-2094-4-3</a>. PMC<span>&nbsp;</span><span class="cs1-lock-free"><a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1781426  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1781426'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1781426" class="external text external">1781426</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/17207275  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/17207275'" tppabs="https://pubmed.ncbi.nlm.nih.gov/17207275" class="external text external">17207275</a>.</cite></span></li><li id="cite_note-11"> <span id="mw-reference-text-cite_note-11" class="mw-reference-text"><cite id="CITEREFShahMenonCabreraVahratian2010" class="citation journal cs1">Shah, Divya K.; Menon, K.M.J.; Cabrera, Lourdes M.; Vahratian, Anjel; Kavoussi, Shahryar K.; Lebovic, Dan I. (2010). <a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2847675  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2847675'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2847675" class="external text external">"Thiazolidinediones decrease vascular endothelial growth factor (VEGF) production by human luteinized granulosa cells in vitro"</a>. <i>Fertility and Sterility</i>. <b>93</b> (6): 2042–7. doi:<a href="javascript:if(confirm('https://doi.org/10.1016%2Fj.fertnstert.2009.02.059  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1016%2Fj.fertnstert.2009.02.059'" tppabs="https://doi.org/10.1016%2Fj.fertnstert.2009.02.059" class="external text external">10.1016/j.fertnstert.2009.02.059</a>. PMC<span>&nbsp;</span><span class="cs1-lock-free"><a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2847675  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2847675'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2847675" class="external text external">2847675</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/19342033  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/19342033'" tppabs="https://pubmed.ncbi.nlm.nih.gov/19342033" class="external text external">19342033</a>.</cite></span></li><li id="cite_note-trials-12"> <span id="mw-reference-text-cite_note-trials-12" class="mw-reference-text"><a href="javascript:if(confirm('http://clinicaltrials.gov/ct/search?term=rosiglitazone&submit=Search  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://clinicaltrials.gov/ct/search?term=rosiglitazone&submit=Search'" tppabs="http://clinicaltrials.gov/ct/search?term=rosiglitazone&submit=Search" class="external text external">Clinical Trials for Rosiglitazone</a> - from ClinicalTrials.gov, a service of the U.S. National Institutes of Health</span></li><li id="cite_note-13"> <span id="mw-reference-text-cite_note-13" class="mw-reference-text"><cite id="CITEREFChitturi2008" class="citation journal cs1">Chitturi, Shivakumar (November 2008). <a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3002502  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3002502'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3002502" class="external text external">"Treatment Options for Nonalcoholic Fatty Liver Disease"</a>. <i>Therapeutic Advances in Gastroenterology</i>. <b>1</b> (3): 173–189. doi:<a href="javascript:if(confirm('https://doi.org/10.1177%2F1756283X08096951  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1177%2F1756283X08096951'" tppabs="https://doi.org/10.1177%2F1756283X08096951" class="external text external">10.1177/1756283X08096951</a>. ISSN<span>&nbsp;</span><a href="javascript:if(confirm('https://www.worldcat.org/issn/1756-283X  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.worldcat.org/issn/1756-283X'" tppabs="https://www.worldcat.org/issn/1756-283X" class="external text external">1756-283X</a>. PMC<span>&nbsp;</span><span class="cs1-lock-free"><a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3002502  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3002502'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3002502" class="external text external">3002502</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/21180527  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/21180527'" tppabs="https://pubmed.ncbi.nlm.nih.gov/21180527" class="external text external">21180527</a>.</cite></span></li><li id="cite_note-14"> <span id="mw-reference-text-cite_note-14" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://web.archive.org/web/20071021074525/http://forbes.com/forbeslife/health/feeds/hscout/2007/08/14/hscout607350.html  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20071021074525/http://forbes.com/forbeslife/health/feeds/hscout/2007/08/14/hscout607350.html'" tppabs="https://web.archive.org/web/20071021074525/http://forbes.com/forbeslife/health/feeds/hscout/2007/08/14/hscout607350.html" class="external text external">"Avandia to Carry Stronger Heart Failure Warning - Forbes.com"</a>. Archived from <a href="javascript:if(confirm('https://www.forbes.com/forbeslife/health/feeds/hscout/2007/08/14/hscout607350.html  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.forbes.com/forbeslife/health/feeds/hscout/2007/08/14/hscout607350.html'" tppabs="https://www.forbes.com/forbeslife/health/feeds/hscout/2007/08/14/hscout607350.html" class="external text external">the original</a> on 21 October 2007<span class="reference-accessdate">. Retrieved <span class="nowrap">15 August</span> 2007</span>.</cite></span></li><li id="cite_note-15"> <span id="mw-reference-text-cite_note-15" class="mw-reference-text"><cite id="CITEREFCharbonnelDormandyErdmannMassi-Benedetti2004" class="citation journal cs1">Charbonnel, B.; Dormandy, J.; Erdmann, E.; Massi-Benedetti, M.; Skene, A.; Proactive Study, Group (2004). <a href="javascript:if(confirm('https://doi.org/10.2337/diacare.27.7.1647  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.2337/diacare.27.7.1647'" tppabs="https://doi.org/10.2337/diacare.27.7.1647" class="external text external">"The Prospective Pioglitazone Clinical Trial in Macrovascular Events (PROactive): Can pioglitazone reduce cardiovascular events in diabetes? Study design and baseline characteristics of 5,238 patients"</a>. <i>Diabetes Care</i>. <b>27</b> (7): 1647–53. doi:<span class="cs1-lock-free"><a href="javascript:if(confirm('https://doi.org/10.2337%2Fdiacare.27.7.1647  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.2337%2Fdiacare.27.7.1647'" tppabs="https://doi.org/10.2337%2Fdiacare.27.7.1647" class="external text external">10.2337/diacare.27.7.1647</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/15220241  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/15220241'" tppabs="https://pubmed.ncbi.nlm.nih.gov/15220241" class="external text external">15220241</a>.</cite></span></li><li id="cite_note-Pioglitazone_and_cardiovascular_risk-16"> <span id="mw-reference-text-cite_note-Pioglitazone_and_cardiovascular_risk-16" class="mw-reference-text"><cite id="CITEREFMannucciMonamiLamannaGensini2008" class="citation journal cs1">Mannucci, E.; Monami, M.; Lamanna, C.; Gensini, G. F.; Marchionni, N. (2008). "Pioglitazone and cardiovascular risk. A comprehensive meta-analysis of randomized clinical trials". <i>Diabetes, Obesity and Metabolism</i>. <b>10</b> (12): 1221–38. doi:<a href="javascript:if(confirm('https://doi.org/10.1111%2Fj.1463-1326.2008.00892.x  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1111%2Fj.1463-1326.2008.00892.x'" tppabs="https://doi.org/10.1111%2Fj.1463-1326.2008.00892.x" class="external text external">10.1111/j.1463-1326.2008.00892.x</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/18505403  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/18505403'" tppabs="https://pubmed.ncbi.nlm.nih.gov/18505403" class="external text external">18505403</a>.</cite></span></li><li id="cite_note-Nissen-17"> <span id="mw-reference-text-cite_note-Nissen-17" class="mw-reference-text"><cite id="CITEREFNissenNichollsWolskiNesto2008" class="citation journal cs1">Nissen, Steven E.; Nicholls, Stephen J.; Wolski, Kathy; Nesto, Richard; Kupfer, Stuart; Perez, Alfonso; Jure, Horacio; De Larochellière, Robert; Staniloae, Cezar S.; Mavromatis, Kreton; Saw, Jacqueline; Hu, Bo; Lincoff, A. Michael; Tuzcu, E. Murat; Periscope Investigators, for the (2008). <a href="javascript:if(confirm('https://doi.org/10.1001/jama.299.13.1561  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1001/jama.299.13.1561'" tppabs="https://doi.org/10.1001/jama.299.13.1561" class="external text external">"Comparison of Pioglitazone vs Glimepiride on Progression of Coronary Atherosclerosis in Patients with Type 2 Diabetes"</a>. <i>JAMA</i>. <b>299</b> (13): 1561–73. doi:<span class="cs1-lock-free"><a href="javascript:if(confirm('https://doi.org/10.1001%2Fjama.299.13.1561  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1001%2Fjama.299.13.1561'" tppabs="https://doi.org/10.1001%2Fjama.299.13.1561" class="external text external">10.1001/jama.299.13.1561</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/18378631  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/18378631'" tppabs="https://pubmed.ncbi.nlm.nih.gov/18378631" class="external text external">18378631</a>.</cite></span></li><li id="cite_note-18"> <span id="mw-reference-text-cite_note-18" class="mw-reference-text"><a href="javascript:if(confirm('https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm376516.htm%5B%5D  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm376516.htm%5B%5D'" tppabs="https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm376516.htm%5B%5D" class="external free external">https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm376516.htm%5B%5D</a></span></li><li id="cite_note-19"> <span id="mw-reference-text-cite_note-19" class="mw-reference-text"><cite id="CITEREFMahaffeyHafleyDickersonBurns2013" class="citation journal cs1">Mahaffey, Kenneth W.; Hafley, Gail; Dickerson, Sheila; Burns, Shana; Tourt-Uhlig, Sandra; White, Jennifer; Newby, L. Kristin; Komajda, Michel; McMurray, John; Bigelow, Robert; Home, Philip D.; Lopes, Renato D. (2013). <a href="javascript:if(confirm('https://doi.org/10.1016/j.ahj.2013.05.004  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1016/j.ahj.2013.05.004'" tppabs="https://doi.org/10.1016/j.ahj.2013.05.004" class="external text external">"Results of a reevaluation of cardiovascular outcomes in the RECORD trial"</a>. <i>American Heart Journal</i>. <b>166</b> (2): 240–249.e1. doi:<span class="cs1-lock-free"><a href="javascript:if(confirm('https://doi.org/10.1016%2Fj.ahj.2013.05.004  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1016%2Fj.ahj.2013.05.004'" tppabs="https://doi.org/10.1016%2Fj.ahj.2013.05.004" class="external text external">10.1016/j.ahj.2013.05.004</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/23895806  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/23895806'" tppabs="https://pubmed.ncbi.nlm.nih.gov/23895806" class="external text external">23895806</a>.</cite></span></li><li id="cite_note-Ferwana2013-20"> <span id="mw-reference-text-cite_note-Ferwana2013-20" class="mw-reference-text"><cite id="CITEREFFerwanaFirwanaHasanAl-Mallah2013" class="citation journal cs1">Ferwana M, Firwana B, Hasan R, Al-Mallah MH, Kim S, Montori VM, Murad MH (September 2013). "Pioglitazone and risk of bladder cancer: a meta-analysis of controlled studies". <i>Diabetes Medicine</i>. <b>30</b> (9): 1026–32. doi:<a href="javascript:if(confirm('https://doi.org/10.1111%2Fdme.12144  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1111%2Fdme.12144'" tppabs="https://doi.org/10.1111%2Fdme.12144" class="external text external">10.1111/dme.12144</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/23350856  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/23350856'" tppabs="https://pubmed.ncbi.nlm.nih.gov/23350856" class="external text external">23350856</a>.</cite></span></li><li id="cite_note-Man&amp;Dic2015-21"> <span id="mw-reference-text-cite_note-Man&amp;Dic2015-21" class="mw-reference-text"><cite id="CITEREFMannucciDicembrini2015" class="citation journal cs1">Mannucci E, Dicembrini I (May–August 2015). <a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4625768  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4625768'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4625768" class="external text external">"Drugs for type 2 diabetes: role in the regulation of bone metabolism"</a>. <i>Clin Cases Miner Bone Metab</i>. <b>12</b> (2): 130–134. doi:<a href="javascript:if(confirm('https://doi.org/10.11138%2Fccmbm%2F2015.12.2.130  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.11138%2Fccmbm%2F2015.12.2.130'" tppabs="https://doi.org/10.11138%2Fccmbm%2F2015.12.2.130" class="external text external">10.11138/ccmbm/2015.12.2.130</a>. PMC<span>&nbsp;</span><span class="cs1-lock-free"><a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4625768  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4625768'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4625768" class="external text external">4625768</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/26604937  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/26604937'" tppabs="https://pubmed.ncbi.nlm.nih.gov/26604937" class="external text external">26604937</a>.</cite></span></li><li id="cite_note-FengKaraRoth2020-22"> <span id="mw-reference-text-cite_note-FengKaraRoth2020-22" class="mw-reference-text"><cite id="CITEREFFengKarakiulakisRoth2020" class="citation journal cs1">Feng L, Karakiulakis G, Roth M (11 March 2020). <a href="javascript:if(confirm('https://doi.org/10.1016/S2213-2600(20)30116-8  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1016/S2213-2600(20)30116-8'" tppabs="https://doi.org/10.1016/S2213-2600(20)30116-8" class="external text external">"Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection?"</a>. <i>The Lancet Respiratory Medicine</i>. doi:<span class="cs1-lock-free"><a href="javascript:if(confirm('https://doi.org/10.1016%2FS2213-2600%2820%2930116-8  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1016%2FS2213-2600%2820%2930116-8'" tppabs="https://doi.org/10.1016%2FS2213-2600%2820%2930116-8" class="external text external">10.1016/S2213-2600(20)30116-8</a></span>.</cite></span></li></ol></div>

<div role="navigation" class="navbox" aria-labelledby="Oral_anti-diabetic_drugs,_insulins_and_insulin_analogs,_and_other_drugs_used_in_diabetes_(A10)" style="padding:3px"><table class="nowraplinks mw-collapsible expanded navbox-inner" style="border-spacing:0;background:transparent;color:inherit"><tbody><tr><th scope="col" class="navbox-title" colspan="2"><div id="Oral_anti-diabetic_drugs,_insulins_and_insulin_analogs,_and_other_drugs_used_in_diabetes_(A10)" style="font-size:114%;margin:0 4em">Oral anti-diabetic drugs, <a href="Insulin.htm" tppabs="https://ptable.com/wiki/compounds/A/Insulin" title="Insulin">insulins</a> and insulin analogs, and other drugs used in diabetes (A10)</div></th></tr><tr><td colspan="2" class="navbox-list navbox-odd hlist" style="width:100%;padding:0px"><div style="padding:0em 0.25em"></div><table class="nowraplinks mw-collapsible mw-collapsed navbox-subgroup" style="border-spacing:0"><tbody><tr><th scope="col" class="navbox-title" colspan="2"><div id="Insulins/insulin_analogs" style="font-size:114%;margin:0 4em"><a href="Insulin.htm" tppabs="https://ptable.com/wiki/compounds/A/Insulin" title="Insulin">Insulins</a>/insulin analogs</div></th></tr><tr><td colspan="2" class="navbox-list navbox-odd" style="width:100%;padding:0px"><div style="padding:0em 0.25em"></div><table class="nowraplinks navbox-subgroup" style="border-spacing:0"><tbody><tr><th scope="row" class="navbox-group" style="width:1%"><i>fast-acting</i></th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>Insulin aspart</li>
<li>Insulin glulisine</li>
<li>Insulin lispro</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%"><i>short-acting</i></th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>Regular insulin</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%"><i>long-acting</i></th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>Insulin detemir</li>
<li>Insulin glargine (+lixisenatide)</li>
<li>NPH insulin</li>
<li>Lente insulin<sup>‡</sup></li>
<li>Ultralente insulin<sup>‡</sup></li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%"><i>ultra-long-acting</i></th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>Insulin degludec (+insulin aspart, +liraglutide)</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%"><i>inhalable</i></th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>Exubera<sup>‡</sup></li>
<li>Afreeza</li></ul>
</div></td></tr></tbody></table><div>
<div class="hlist">
<ul><li><sup>#</sup>WHO-EM</li>
<li><sup>‡</sup>Withdrawn from market</li>
<li>Clinical trials:
<ul><li><sup>†</sup>Phase III</li>
<li><sup>§</sup>Never to phase III</li></ul></li></ul>
</div></div></td></tr></tbody></table><div></div></td></tr><tr><td colspan="2" class="navbox-list navbox-odd hlist" style="width:100%;padding:0px"><div style="padding:0em 0.25em"></div><table class="nowraplinks mw-collapsible mw-collapsed navbox-subgroup" style="border-spacing:0"><tbody><tr><th scope="col" class="navbox-title" colspan="2"><div id="Non-insulins" style="font-size:114%;margin:0 4em">Non-insulins</div></th></tr><tr><td colspan="2" class="navbox-list navbox-odd" style="width:100%;padding:0px"><div style="padding:0em 0.25em"></div><table class="nowraplinks navbox-subgroup" style="border-spacing:0"><tbody><tr><th scope="row" class="navbox-group" style="width:1%">Insulin sensitizers</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em"></div><table class="nowraplinks navbox-subgroup" style="border-spacing:0"><tbody><tr><th scope="row" class="navbox-group" style="width:1%">Biguanides</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><a href="Buformin.htm" tppabs="https://ptable.com/wiki/compounds/A/Buformin" title="Buformin">Buformin</a><sup>‡</sup></li>
<li><a href="Metformin.htm" tppabs="https://ptable.com/wiki/compounds/A/Metformin" title="Metformin">Metformin</a><sup>#</sup></li>
<li><a href="Phenformin.htm" tppabs="https://ptable.com/wiki/compounds/A/Phenformin" title="Phenformin">Phenformin</a><sup>‡</sup></li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%"><a href="Thiazolidinedione.htm" tppabs="https://ptable.com/wiki/compounds/A/Thiazolidinedione" title="Thiazolidinedione">TZDs</a>/"glitazones" (PPAR)</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>Ciglitazone<sup>§</sup></li>
<li>Darglitazone<sup>§</sup></li>
<li>Englitazone<sup>§</sup></li>
<li>Lobeglitazone</li>
<li>Netoglitazone<sup>§</sup></li>
<li><a href="Pioglitazone.htm" tppabs="https://ptable.com/wiki/compounds/A/Pioglitazone" title="Pioglitazone">Pioglitazone</a></li>
<li>Rivoglitazone<sup>†</sup></li>
<li><a href="javascript:if(confirm('https://ptable.com/wiki/compounds/A/Rosiglitazone  \n\nThis file was not retrieved by Teleport VLX, because it was unavailable, or its retrieval was aborted, or the project was stopped too soon.  \n\nDo you want to open it from the server?'))window.location='https://ptable.com/wiki/compounds/A/Rosiglitazone'" tppabs="https://ptable.com/wiki/compounds/A/Rosiglitazone" title="Rosiglitazone">Rosiglitazone</a></li>
<li><a href="Troglitazone.htm" tppabs="https://ptable.com/wiki/compounds/A/Troglitazone" title="Troglitazone">Troglitazone</a><sup>‡</sup></li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Dual PPAR agonists</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>Aleglitazar<sup>†</sup></li>
<li>Muraglitazar<sup>§</sup></li>
<li>Saroglitazar</li>
<li>Tesaglitazar<sup>§</sup></li></ul>
</div></td></tr></tbody></table><div></div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Secretagogues</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em"></div><table class="nowraplinks navbox-subgroup" style="border-spacing:0"><tbody><tr><th scope="row" class="navbox-group" style="width:1%">K<sup>+</sup><sub>ATP</sub></th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em"></div><table class="nowraplinks navbox-subgroup" style="border-spacing:0"><tbody><tr><th scope="row" class="navbox-group" style="width:1%">Sulfonylureas</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>1st generation</i>: <a href="Acetohexamide.htm" tppabs="https://ptable.com/wiki/compounds/A/Acetohexamide" title="Acetohexamide">Acetohexamide</a></li>
<li><a href="Carbutamide.htm" tppabs="https://ptable.com/wiki/compounds/A/Carbutamide" title="Carbutamide">Carbutamide</a></li>
<li><a href="Chlorpropamide.htm" tppabs="https://ptable.com/wiki/compounds/A/Chlorpropamide" title="Chlorpropamide">Chlorpropamide</a></li>
<li><span class="new">Glycyclamide</span></li>
<li>Metahexamide</li>
<li><a href="Tolazamide.htm" tppabs="https://ptable.com/wiki/compounds/A/Tolazamide" title="Tolazamide">Tolazamide</a></li>
<li><a href="Tolbutamide.htm" tppabs="https://ptable.com/wiki/compounds/A/Tolbutamide" title="Tolbutamide">Tolbutamide</a></li></ul>

<ul><li><i>2nd generation</i>: <a href="Glibenclamide.htm" tppabs="https://ptable.com/wiki/compounds/A/Glibenclamide" title="Glibenclamide">Glibenclamide (glyburide)</a></li>
<li>Glibornuride</li>
<li>Glicaramide</li>
<li><a href="Gliclazide.htm" tppabs="https://ptable.com/wiki/compounds/A/Gliclazide" title="Gliclazide">Gliclazide</a><sup>#</sup></li>
<li><a href="Glimepiride.htm" tppabs="https://ptable.com/wiki/compounds/A/Glimepiride" title="Glimepiride">Glimepiride</a></li>
<li><a href="Glipizide.htm" tppabs="https://ptable.com/wiki/compounds/A/Glipizide" title="Glipizide">Glipizide</a></li>
<li><a href="Gliquidone.htm" tppabs="https://ptable.com/wiki/compounds/A/Gliquidone" title="Gliquidone">Gliquidone</a></li>
<li><a href="Glisoxepide.htm" tppabs="https://ptable.com/wiki/compounds/A/Glisoxepide" title="Glisoxepide">Glisoxepide</a></li>
<li>Glyclopyramide</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Meglitinides/"glinides"</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><a href="Mitiglinide.htm" tppabs="https://ptable.com/wiki/compounds/A/Mitiglinide" title="Mitiglinide">Mitiglinide</a></li>
<li><a href="Nateglinide.htm" tppabs="https://ptable.com/wiki/compounds/A/Nateglinide" title="Nateglinide">Nateglinide</a></li>
<li><a href="Repaglinide.htm" tppabs="https://ptable.com/wiki/compounds/A/Repaglinide" title="Repaglinide">Repaglinide</a></li></ul>
</div></td></tr></tbody></table><div></div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">GLP-1 receptor agonists</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>Albiglutide<sup>‡</sup></li>
<li>Dulaglutide</li>
<li><a href="Exenatide.htm" tppabs="https://ptable.com/wiki/compounds/A/Exenatide" title="Exenatide">Exenatide</a></li>
<li>Liraglutide</li>
<li>Lixisenatide</li>
<li>Semaglutide</li>
<li>Taspoglutide<sup>†</sup></li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">DPP-4 inhibitors/"gliptins"</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>Alogliptin</li>
<li>Anagliptin</li>
<li>Evogliptin</li>
<li><span class="new">Garvagliptin</span></li>
<li>Gemigliptin</li>
<li>Gosogliptin</li>
<li>Linagliptin</li>
<li><span class="new">Melogliptin</span></li>
<li>Omarigliptin</li>
<li>Saxagliptin</li>
<li><a href="Sitagliptin.htm" tppabs="https://ptable.com/wiki/compounds/A/Sitagliptin" title="Sitagliptin">Sitagliptin</a></li>
<li>Teneligliptin</li>
<li>Trelagliptin</li>
<li>Vildagliptin</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%"> FFAR1 agonists</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><span class="new">Fasiglifam</span><sup>†</sup></li></ul>
</div></td></tr></tbody></table><div></div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Other</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em"></div><table class="nowraplinks navbox-subgroup" style="border-spacing:0"><tbody><tr><th scope="row" class="navbox-group" style="width:1%">Aldose reductase inhibitors</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><a href="Epalrestat.htm" tppabs="https://ptable.com/wiki/compounds/A/Epalrestat" title="Epalrestat">Epalrestat</a></li>
<li>Fidarestat<sup>§</sup></li>
<li>Ranirestat<sup>†</sup></li>
<li><a href="Tolrestat.htm" tppabs="https://ptable.com/wiki/compounds/A/Tolrestat" title="Tolrestat">Tolrestat</a><sup>‡</sup></li>
<li>Zenarestat<sup>§</sup></li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Alpha-glucosidase inhibitors</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><a href="Acarbose.htm" tppabs="https://ptable.com/wiki/compounds/A/Acarbose" title="Acarbose">Acarbose</a></li>
<li><a href="Miglitol.htm" tppabs="https://ptable.com/wiki/compounds/A/Miglitol" title="Miglitol">Miglitol</a></li>
<li><a href="Voglibose.htm" tppabs="https://ptable.com/wiki/compounds/A/Voglibose" title="Voglibose">Voglibose</a></li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Amylin analog</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><a href="Pramlintide.htm" tppabs="https://ptable.com/wiki/compounds/A/Pramlintide" title="Pramlintide">Pramlintide</a></li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">SGLT2 inhibitors/"gliflozins"</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>Canagliflozin</li>
<li>Dapagliflozin</li>
<li>Empagliflozin</li>
<li>Ertugliflozin</li>
<li>Ipragliflozin</li>
<li>Remogliflozin<sup>§</sup></li>
<li>Sergliflozin<sup>§</sup></li>
<li>Tofogliflozin<sup>†</sup></li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Other</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>Benfluorex<sup>‡</sup></li>
<li><a href="Bromocriptine.htm" tppabs="https://ptable.com/wiki/compounds/A/Bromocriptine" title="Bromocriptine">Bromocriptine</a></li></ul>
</div></td></tr></tbody></table><div></div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Combinations</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em"></div><table class="nowraplinks navbox-subgroup" style="border-spacing:0"><tbody><tr><td colspan="2" class="navbox-list navbox-even" style="width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>Alogliptin/metformin</li>
<li>Canagliflozin/metformin</li>
<li>Dapagliflozin/metformin</li>
<li>Dapagliflozin/saxagliptin</li>
<li>Dapagliflozin/saxagliptin/metformin</li>
<li>Empagliflozin/metformin</li>
<li><span class="new">Gemigliptin/rosuvastatin</span></li>
<li>Glibenclamide (glyburide)/metformin</li>
<li><span class="new">Glimepiride/rosiglitazone</span></li>
<li><span class="new">Linagliptin/empagliflozin</span></li>
<li><a href="Metformin.htm" tppabs="https://ptable.com/wiki/compounds/A/Linagliptin/metformin" title="Linagliptin/metformin" class="mw-redirect">Linagliptin/metformin</a></li>
<li><span class="new">Metformin/acarbose</span></li>
<li>Metformin/ertugliflozin</li>
<li><span class="new">Metformin/evogliptin</span></li>
<li><span class="new">Metformin/gemigliptin</span></li>
<li><span class="new">Metformin/repaglinide</span></li>
<li><span class="new">Metformin/sulfonylureas</span></li>
<li><span class="new">Phenformin/sulfonylureas</span></li>
<li>Pioglitazone/alogliptin</li>
<li>Pioglitazone/glimepiride</li>
<li>Pioglitazone/metformin</li>
<li><span class="new">Pioglitazone/sitagliptin</span></li>
<li><a href="Metformin.htm" tppabs="https://ptable.com/wiki/compounds/A/Rosiglitazone/metformin" title="Rosiglitazone/metformin" class="mw-redirect">Rosiglitazone/metformin</a></li>
<li><a href="Metformin.htm" tppabs="https://ptable.com/wiki/compounds/A/Saxagliptin/metformin" title="Saxagliptin/metformin" class="mw-redirect">Saxagliptin/metformin</a></li>
<li><span class="new">Sitagliptin/ertugliflozin</span></li>
<li>Sitagliptin/metformin</li>
<li>Sitagliptin/simvastatin</li>
<li>Vildagliptin/metformin</li></ul>
</div></td></tr></tbody></table><div></div></td></tr></tbody></table><div>
<div class="hlist">
<ul><li><sup>#</sup>WHO-EM</li>
<li><sup>‡</sup>Withdrawn from market</li>
<li>Clinical trials:
<ul><li><sup>†</sup>Phase III</li>
<li><sup>§</sup>Never to phase III</li></ul></li></ul>
</div></div></td></tr></tbody></table><div></div></td></tr></tbody></table></div><span>
</span>
<div role="navigation" class="navbox" aria-labelledby="PPAR_modulators" style="padding:3px"><table class="nowraplinks hlist mw-collapsible mw-collapsed navbox-inner" style="border-spacing:0;background:transparent;color:inherit"><tbody><tr><th scope="col" class="navbox-title" colspan="2"><div id="PPAR_modulators" style="font-size:114%;margin:0 4em"><abbr>PPAR</abbr> modulators</div></th></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;"><abbr>PPARα</abbr></th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Agonists:</i> 15-HETE</li>
<li><span class="new">15-HpETE</span></li>
<li>Aleglitazar</li>
<li>Aluminium clofibrate</li>
<li><a href="Arachidonic_acid.htm" tppabs="https://ptable.com/wiki/compounds/A/Arachidonic_acid" title="Arachidonic acid">Arachidonic acid</a></li>
<li><a href="Bezafibrate.htm" tppabs="https://ptable.com/wiki/compounds/A/Bezafibrate" title="Bezafibrate">Bezafibrate</a></li>
<li><a href="Clofibrate.htm" tppabs="https://ptable.com/wiki/compounds/A/Clofibrate" title="Clofibrate">Clofibrate</a></li>
<li><span class="new">CP-775146</span></li>
<li><a href="Daidzein.htm" tppabs="https://ptable.com/wiki/compounds/A/Daidzein" title="Daidzein">Daidzein</a></li>
<li><a href="Dehydroepiandrosterone.htm" tppabs="https://ptable.com/wiki/compounds/A/Dehydroepiandrosterone" title="Dehydroepiandrosterone">DHEA</a> (prasterone) (in rodents)</li>
<li>Elafibranor</li>
<li>Etomoxir</li>
<li><a href="Fenofibrate.htm" tppabs="https://ptable.com/wiki/compounds/A/Fenofibrate" title="Fenofibrate">Fenofibrate</a></li>
<li><a href="Genistein.htm" tppabs="https://ptable.com/wiki/compounds/A/Genistein" title="Genistein">Genistein</a></li>
<li><a href="Gemfibrozil.htm" tppabs="https://ptable.com/wiki/compounds/A/Gemfibrozil" title="Gemfibrozil">Gemfibrozil</a></li>
<li><span class="new">GW-7647</span></li>
<li><span class="new">Lanifibranor</span></li>
<li>Leukotriene B<sub>4</sub></li>
<li><span class="new">LG-101506</span></li>
<li><span class="new">LG-100754</span></li>
<li>Lobeglitazone</li>
<li>Muraglitazar</li>
<li>Oleylethanolamide</li>
<li>Palmitoylethanolamide</li>
<li>Pemafibrate</li>
<li><a href="Perfluorononanoic_acid.htm" tppabs="https://ptable.com/wiki/compounds/A/Perfluorononanoic_acid" title="Perfluorononanoic acid">Perfluorononanoic acid</a></li>
<li><a href="Perfluorooctanoic_acid.htm" tppabs="https://ptable.com/wiki/compounds/A/Perfluorooctanoic_acid" title="Perfluorooctanoic acid">Perfluorooctanoic acid</a></li>
<li><a href="Pioglitazone.htm" tppabs="https://ptable.com/wiki/compounds/A/Pioglitazone" title="Pioglitazone">Pioglitazone</a></li>
<li>Saroglitazar</li>
<li>Sodelglitazar</li>
<li>Tesaglitazar</li>
<li>Tetradecylthioacetic acid</li>
<li><a href="Troglitazone.htm" tppabs="https://ptable.com/wiki/compounds/A/Troglitazone" title="Troglitazone">Troglitazone</a></li>
<li><span class="new">WY-14643</span></li></ul>

<ul><li><i>Antagonists:</i> <span class="new">GW-6471</span></li>
<li>MK-886</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;"><abbr>PPARδ</abbr></th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Agonists:</i> 15-HETE</li>
<li><span class="new">15-HpETE</span></li>
<li><a href="Arachidonic_acid.htm" tppabs="https://ptable.com/wiki/compounds/A/Arachidonic_acid" title="Arachidonic acid">Arachidonic acid</a></li>
<li><a href="Bezafibrate.htm" tppabs="https://ptable.com/wiki/compounds/A/Bezafibrate" title="Bezafibrate">Bezafibrate</a></li>
<li><a href="Daidzein.htm" tppabs="https://ptable.com/wiki/compounds/A/Daidzein" title="Daidzein">Daidzein</a></li>
<li>Elafibranor</li>
<li><span class="new">Fonadelpar</span></li>
<li><a href="Genistein.htm" tppabs="https://ptable.com/wiki/compounds/A/Genistein" title="Genistein">Genistein</a></li>
<li>GW-0742</li>
<li>GW-501516</li>
<li><span class="new">L-165,041</span></li>
<li><span class="new">Lanifibranor</span></li>
<li><span class="new">LG-101506</span></li>
<li>Seladelpar</li>
<li>Sodelglitazar</li>
<li>Tetradecylthioacetic acid</li></ul>

<ul><li><i>Antagonists:</i> <span class="new">FH-535</span></li>
<li><span class="new">GSK-0660</span></li>
<li><span class="new">GSK-3787</span></li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;"><abbr>PPARγ</abbr></th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Agonists:</i> <span class="new">5-Oxo-ETE</span></li>
<li><span class="new">5-Oxo-15-hydroxy-ETE</span></li>
<li>15-Deoxy-Δ<sup>12,14</sup>-prostaglandin J<sub>2</sub></li>
<li>15-HETE</li>
<li><span class="new">15-HpETE</span></li>
<li>Aleglitazar</li>
<li><a href="Arachidonic_acid.htm" tppabs="https://ptable.com/wiki/compounds/A/Arachidonic_acid" title="Arachidonic acid">Arachidonic acid</a></li>
<li><span class="new">Balaglitazone</span></li>
<li><a href="Berberine.htm" tppabs="https://ptable.com/wiki/compounds/A/Berberine" title="Berberine">Berberine</a></li>
<li><a href="Bezafibrate.htm" tppabs="https://ptable.com/wiki/compounds/A/Bezafibrate" title="Bezafibrate">Bezafibrate</a></li>
<li><a href="Cannabidiol.htm" tppabs="https://ptable.com/wiki/compounds/A/Cannabidiol" title="Cannabidiol">Cannabidiol</a></li>
<li><span class="new">Cevoglitazar</span></li>
<li>Ciglitazone</li>
<li><a href="Daidzein.htm" tppabs="https://ptable.com/wiki/compounds/A/Daidzein" title="Daidzein">Daidzein</a></li>
<li>Darglitazone</li>
<li><span class="new">Edaglitazone</span></li>
<li><span class="new">Efatutazone</span></li>
<li>Englitazone</li>
<li>Etalocib</li>
<li>Farglitazar</li>
<li><a href="Genistein.htm" tppabs="https://ptable.com/wiki/compounds/A/Genistein" title="Genistein">Genistein</a></li>
<li><span class="new">GW-1929</span></li>
<li><a href="Ibuprofen.htm" tppabs="https://ptable.com/wiki/compounds/A/Ibuprofen" title="Ibuprofen">Ibuprofen</a></li>
<li><span class="new">Imiglitazar</span></li>
<li>Indeglitazar</li>
<li><span class="new">Lanifibranor</span></li>
<li><span class="new">LG-100268</span></li>
<li><span class="new">LG-100754</span></li>
<li><span class="new">LG-101506</span></li>
<li>Lobeglitazone</li>
<li>Muraglitazar (muroglitazar)</li>
<li><span class="new">nTZDpa</span></li>
<li><span class="new">Naveglitazar</span></li>
<li>Netoglitazone</li>
<li><span class="new">Oxeglitazar</span></li>
<li><span class="new">Peliglitazar</span></li>
<li><span class="new">Pemaglitazar</span></li>
<li><a href="Perfluorononanoic_acid.htm" tppabs="https://ptable.com/wiki/compounds/A/Perfluorononanoic_acid" title="Perfluorononanoic acid">Perfluorononanoic acid</a></li>
<li><a href="Pioglitazone.htm" tppabs="https://ptable.com/wiki/compounds/A/Pioglitazone" title="Pioglitazone">Pioglitazone</a></li>
<li><span class="new">Prostaglandin J<sub>2</sub></span></li>
<li><span class="new">Ragaglitazar</span></li>
<li><span class="new">Reglitazar</span></li>
<li>Rivoglitazone</li>
<li><a href="javascript:if(confirm('https://ptable.com/wiki/compounds/A/Rosiglitazone  \n\nThis file was not retrieved by Teleport VLX, because it was unavailable, or its retrieval was aborted, or the project was stopped too soon.  \n\nDo you want to open it from the server?'))window.location='https://ptable.com/wiki/compounds/A/Rosiglitazone'" tppabs="https://ptable.com/wiki/compounds/A/Rosiglitazone" title="Rosiglitazone">Rosiglitazone</a></li>
<li><span class="new">RS5444</span></li>
<li>Saroglitazar</li>
<li><span class="new">Sipoglitazar</span></li>
<li>Sodelglitazar</li>
<li><a href="Telmisartan.htm" tppabs="https://ptable.com/wiki/compounds/A/Telmisartan" title="Telmisartan">Telmisartan</a></li>
<li>Tesaglitazar</li>
<li><a href="Troglitazone.htm" tppabs="https://ptable.com/wiki/compounds/A/Troglitazone" title="Troglitazone">Troglitazone</a></li></ul>

<ul><li><i><abbr>SPPARMs</abbr>:</i> <a href="Bisphenol_A_diglycidyl_ether.htm" tppabs="https://ptable.com/wiki/compounds/A/Bisphenol_A_diglycidyl_ether" title="Bisphenol A diglycidyl ether">BADGE</a></li>
<li>EPI-001</li>
<li><span class="new">INT-131</span></li>
<li><span class="new">MK-0533</span></li>
<li><span class="new">S26948</span></li></ul>

<ul><li><i>Antagonists:</i> <span class="new">FH-535</span></li>
<li><span class="new">GW-9662</span></li>
<li><span class="new">SR-202</span></li>
<li><span class="new">T-0070907</span></li></ul>

<ul><li><i>Unknown:</i> <span class="new">SR-1664</span></li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">Non-selective</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Agonists:</i> <a href="Ciprofibrate.htm" tppabs="https://ptable.com/wiki/compounds/A/Ciprofibrate" title="Ciprofibrate">Ciprofibrate</a></li>
<li>Clinofibrate</li>
<li>Clofibride</li>
<li>Englitazone</li>
<li>Etofibrate</li>
<li>Farglitazar</li>
<li>Netoglitazone</li>
<li>Ronifibrate</li>
<li>Rivoglitazone</li>
<li>Simfibrate</li></ul>
</div></td></tr><tr><td class="navbox-abovebelow" colspan="2"><div>
<dl><dt>See also</dt>
<dd><i>Receptor/signaling modulators</i></dd></dl>
</div></td></tr></tbody></table></div><span>
</span>

<style data-mw-deduplicate="TemplateStyles:r951705291">.mw-parser-output cite.citation{font-style:inherit}.mw-parser-output .citation q{quotes:"\"""\"""'""'"}.mw-parser-output .id-lock-free a,.mw-parser-output .citation .cs1-lock-free a{background-image:url("../../../../upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/9px-Lock-green.svg.png"/*tpa=https://upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/9px-Lock-green.svg.png*/);background-image:linear-gradient(transparent,transparent),url("../../../../upload.wikimedia.org/wikipedia/commons/6/65/Lock-green.svg"/*tpa=https://upload.wikimedia.org/wikipedia/commons/6/65/Lock-green.svg*/);background-repeat:no-repeat;background-size:9px;background-position:right .1em center}.mw-parser-output .id-lock-limited a,.mw-parser-output .id-lock-registration a,.mw-parser-output .citation .cs1-lock-limited a,.mw-parser-output .citation .cs1-lock-registration a{background-image:url("../../../../upload.wikimedia.org/wikipedia/commons/thumb/d/d6/Lock-gray-alt-2.svg/9px-Lock-gray-alt-2.svg.png"/*tpa=https://upload.wikimedia.org/wikipedia/commons/thumb/d/d6/Lock-gray-alt-2.svg/9px-Lock-gray-alt-2.svg.png*/);background-image:linear-gradient(transparent,transparent),url("../../../../upload.wikimedia.org/wikipedia/commons/d/d6/Lock-gray-alt-2.svg"/*tpa=https://upload.wikimedia.org/wikipedia/commons/d/d6/Lock-gray-alt-2.svg*/);background-repeat:no-repeat;background-size:9px;background-position:right .1em center}.mw-parser-output .id-lock-subscription a,.mw-parser-output .citation .cs1-lock-subscription a{background-image:url("../../../../upload.wikimedia.org/wikipedia/commons/thumb/a/aa/Lock-red-alt-2.svg/9px-Lock-red-alt-2.svg.png"/*tpa=https://upload.wikimedia.org/wikipedia/commons/thumb/a/aa/Lock-red-alt-2.svg/9px-Lock-red-alt-2.svg.png*/);background-image:linear-gradient(transparent,transparent),url("../../../../upload.wikimedia.org/wikipedia/commons/a/aa/Lock-red-alt-2.svg"/*tpa=https://upload.wikimedia.org/wikipedia/commons/a/aa/Lock-red-alt-2.svg*/);background-repeat:no-repeat;background-size:9px;background-position:right .1em center}.mw-parser-output .cs1-subscription,.mw-parser-output .cs1-registration{color:#555}.mw-parser-output .cs1-subscription span,.mw-parser-output .cs1-registration span{border-bottom:1px dotted;cursor:help}.mw-parser-output .cs1-ws-icon a{background-image:url("../../../../upload.wikimedia.org/wikipedia/commons/thumb/4/4c/Wikisource-logo.svg/12px-Wikisource-logo.svg.png"/*tpa=https://upload.wikimedia.org/wikipedia/commons/thumb/4/4c/Wikisource-logo.svg/12px-Wikisource-logo.svg.png*/);background-image:linear-gradient(transparent,transparent),url("../../../../upload.wikimedia.org/wikipedia/commons/4/4c/Wikisource-logo.svg"/*tpa=https://upload.wikimedia.org/wikipedia/commons/4/4c/Wikisource-logo.svg*/);background-repeat:no-repeat;background-size:12px;background-position:right .1em center}.mw-parser-output code.cs1-code{color:inherit;background:inherit;border:inherit;padding:inherit}.mw-parser-output .cs1-hidden-error{display:none;font-size:100%}.mw-parser-output .cs1-visible-error{font-size:100%}.mw-parser-output .cs1-maint{display:none;color:#33aa33;margin-left:0.3em}.mw-parser-output .cs1-subscription,.mw-parser-output .cs1-registration,.mw-parser-output .cs1-format{font-size:95%}.mw-parser-output .cs1-kern-left,.mw-parser-output .cs1-kern-wl-left{padding-left:0.2em}.mw-parser-output .cs1-kern-right,.mw-parser-output .cs1-kern-wl-right{padding-right:0.2em}.mw-parser-output .citation .mw-selflink{font-weight:inherit}</style>
    
</details><!--htdig_noindex--><div><div style="clear:both; background-image:linear-gradient(180deg, #E8E8E8, white); border-top: dashed 2px #AAAAAA; padding: 0.5em 0.5em 0.5em 0.5em; margin-top: 1em; direction: ltr;">
    This article is issued from <a class="external text" title="Last edited on 2020-04-13" href="javascript:if(confirm('https://en.wikipedia.org/wiki/?title=Thiazolidinedione&oldid=950613331  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://en.wikipedia.org/wiki/?title=Thiazolidinedione&oldid=950613331'" tppabs="https://en.wikipedia.org/wiki/?title=Thiazolidinedione&oldid=950613331">Wikipedia</a>. The text is licensed under <a class="external text" href="javascript:if(confirm('https://creativecommons.org/licenses/by-sa/4.0/  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://creativecommons.org/licenses/by-sa/4.0/'" tppabs="https://creativecommons.org/licenses/by-sa/4.0/">Creative Commons - Attribution - Sharealike</a>. Additional terms may apply for the media files.
</div>
</div><!--/htdig_noindex--></div>
        </div>
      </div>
    </div>
  </div>
  <script src="../-/j/js_modules/jsConfigVars.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/jsConfigVars.js" class=""></script>
  <script src="../-/j/js_modules/startup.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/startup.js" class=""></script>
<script src="../-/j/js_modules/jquery.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/jquery.js" class=""></script>
<script src="../-/j/js_modules/mediawiki.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/mediawiki.js" class=""></script>
<script src="../-/j/js_modules/site.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/site.js" class=""></script>
<script src="../-/j/js_modules/ext.cite.ux-enhancements.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/ext.cite.ux-enhancements.js" class=""></script>



</body></html>